Should you buy Recursion Pharmaceuticals stock now?
No, the technical signal for Recursion Pharmaceuticals is currently SELL. Recursion Pharmaceuticals trades at $3.22 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.063 with rising momentum (signal: -0.087); RSI is at 49.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $7.25 points to 125.5% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Recursion Pharmaceuticals stock?
The average analyst price target for Recursion Pharmaceuticals is $7.25. The current price is $3.22, which gives an upside of 125.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $6.53 and $7.98.
Is Recursion Pharmaceuticals a dividend stock?
No, Recursion Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals is rated as a stock with high risk. the annual standard deviation is 69.9%, which classifies the stock as high risk.
Is Recursion Pharmaceuticals overvalued?
No, Recursion Pharmaceuticals is considered undervalued based on the analyst price target (125.5% upside). Recursion Pharmaceuticals has the following valuation ratios: a P/S ratio of 26.5, a P/B ratio of 1.6. The analyst price target suggests that the stock is undervalued by 125.5%.
Is Recursion Pharmaceuticals overbought?
No, Recursion Pharmaceuticals is not overbought. RSI is at 49.0 (neutral zone). The technical indicators show: RSI is at 49.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.3% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Recursion Pharmaceuticals earnings report?
The date of the next earnings report for Recursion Pharmaceuticals has not been published yet. Check the company's investor calendar for updates.
Is Recursion Pharmaceuticals shorted?
Yes, Recursion Pharmaceuticals is shorted with 36.1% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Recursion Pharmaceuticals stock?
No, insiders are not buying Recursion Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 12 sales. On a net basis, 1,083,450 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 1,949,788 $ sold. Active sellers include Borgeson Blake, Bumpus Namandje, Taylor Ben R and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Recursion Pharmaceuticals a good stock?
Based on our total score, Recursion Pharmaceuticals is rated as a disastrous stock with a total score of 17 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 22/100, Quality: 18/100, Momentum: 12/100. In addition: analysts see 125.5% upside to the price target; technical signal: Strong Sell. Whether Recursion Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Recursion Pharmaceuticals stock?
The outlook for Recursion Pharmaceuticals based on current data: the average analyst price target is $7.25 (+125.5%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Recursion Pharmaceuticals stock rising?
Recursion Pharmaceuticals is rising right now. The technical indicators show: the price is 2.3% above the 20-day average; short interest is 36.1% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Recursion Pharmaceuticals go?
The average analyst price target for Recursion Pharmaceuticals is $7.25, which corresponds to a potential gain of 125.5% from the current price of $3.22. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Recursion Pharmaceuticals fall?
We lack enough history to give a specific floor for Recursion Pharmaceuticals. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Recursion Pharmaceuticals do?
rxrx.us, eller Recursion Pharmaceuticals, driver en biotekvirksomhed i klinisk fase. De knækker den biologiske kode ved at blande teknologi, kemi og data for at gøre udviklingen af medicin mere industriel. Lige nu tester de flere midler. For eksempel er REC-994 i fase 2 mod hj... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Recursion Pharmaceuticals as an investment.
Did Recursion Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Recursion Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Recursion Pharmaceuticals making money or losing money?
We have no current profitability data for Recursion Pharmaceuticals. See the latest report in the earnings history above.
Can Recursion Pharmaceuticals go bankrupt?
The bankruptcy risk of Recursion Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -1.91 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 40% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Recursion Pharmaceuticals have a lot of debt?
No, Recursion Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 40%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
